Horizon Therapeutics (HZNP) Tops Q3 EPS by 22c

Horizon Therapeutics (NASDAQ: HZNP) reported Q3 EPS of $1.75, $0.22 better than the analyst estimate of $1.53. Revenue for the quarter came in at $1.04 billion versus the consensus estimate of $977.52 million.

GUIDANCE:

Horizon Therapeutics raises FY2021 revenue to $3.16-3.21 billion, versus the consensus of $3.12 billion.

For earnings history and earnings-related data on Horizon Therapeutics (HZNP) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Hesai Group (HSAI) Tops Q1 EPS by 8c